Previous Article | Next Article 
Journal of Bacteriology, December 2003, p. 6883-6892, Vol. 185, No. 23
0021-9193/03/$08.00+0 DOI: 10.1128/JB.185.23.6883-6892.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Quinolone Resistance Due to Reduced Target Enzyme Expression
Dilek Ince and David C. Hooper*
Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Received 5 May 2003/
Accepted 29 August 2003
We report for the first time low-level quinolone resistance mediated by decreased expression of topoisomerase IV in Staphylococcus aureus. A single-step mutant of wild-type S. aureus strain ISP794, P18 selected by using twice the MIC of premafloxacin, had four- and four- to eightfold greater MICs of premafloxacin and ciprofloxacin, respectively, than the wild type. Sequencing of parEC and gyrBA with their promoter regions revealed a point mutation (G
A) 13 bp upstream of the start codon of parE. Genetic linkage studies showed that there was a high level of correlation between the mutation and the resistance phenotype, and allelic exchange confirmed the contribution of the mutation to resistance. Decreased expression of ParE and decreased steady-state levels of parEC transcripts in P18 and in resistant allelic exchange mutants were observed. The steady-state levels of gyrBA and topB transcripts were increased in P18 but not in two resistant allelic exchange mutants, and sequencing upstream of either gene did not reveal a difference between ISP794 and P18. The steady-state levels of topA transcripts were similar in the various strains. Growth competition experiments performed at 30, 37, and 41°C with a susceptible allelic exchange strain and a resistant allelic exchange strain suggested that loss of fitness was associated with reduced levels of ParE at 41°C. However, P18 had a growth advantage over ISP794 at all temperatures, suggesting that a compensatory mechanism was associated with the increased levels of gyrBA and topB transcripts. Thus, reduced levels of ParE appear to be compatible with cell survival, although there may be a fitness cost during rapid cell multiplication, which might be overcome by compensatory mechanisms without reversion of the resistance phenotype.
* Corresponding author. Mailing address: Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114-2696. Phone: (617) 726-3812. Fax: (617) 726-7416. E-mail:
dhooper{at}partners.org.
Journal of Bacteriology, December 2003, p. 6883-6892, Vol. 185, No. 23
0021-9193/03/$08.00+0 DOI: 10.1128/JB.185.23.6883-6892.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L., Morris, T. W., Roche, E. D., Yan, D., Lynch, A. S.
(2008). In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus. Antimicrob. Agents Chemother.
52: 2313-2323
[Abstract]
[Full Text]
-
Riordan, J. T., Muthaiyan, A., Van Voorhies, W., Price, C. T., Graham, J. E., Wilkinson, B. J., Gustafson, J. E.
(2007). Response of Staphylococcus aureus to Salicylate Challenge. J. Bacteriol.
189: 220-227
[Abstract]
[Full Text]
-
Bhagwat, S. S., Mundkur, L. A., Gupte, S. V., Patel, M. V., Khorakiwala, H. F.
(2006). The Anti-Methicillin-Resistant Staphylococcus aureus Quinolone WCK 771 Has Potent Activity against Sequentially Selected Mutants, Has a Narrow Mutant Selection Window against Quinolone-Resistant Staphylococcus aureus, and Preferentially Targets DNA Gyrase . Antimicrob. Agents Chemother.
50: 3568-3579
[Abstract]
[Full Text]
-
Strahilevitz, J., Robicsek, A., Hooper, D. C.
(2006). Role of the Extended {alpha}4 Domain of Staphylococcus aureus Gyrase A Protein in Determining Low Sensitivity to Quinolones. Antimicrob. Agents Chemother.
50: 600-606
[Abstract]
[Full Text]
-
Strahilevitz, J., Truong-Bolduc, Q. C., Hooper, D. C.
(2005). DX-619, a Novel Des-Fluoro(6) Quinolone Manifesting Low Frequency of Selection of Resistant Staphylococcus aureus Mutants: Quinolone Resistance beyond Modification of Type II Topoisomerases. Antimicrob. Agents Chemother.
49: 5051-5057
[Abstract]
[Full Text]
-
Korzheva, N., Davies, T. A., Goldschmidt, R.
(2005). Novel Ser79Leu and Ser81Ile Substitutions in the Quinolone Resistance-Determining Regions of ParC Topoisomerase IV and GyrA DNA Gyrase Subunits from Recent Fluoroquinolone-Resistant Streptococcus pneumoniae Clinical Isolates. Antimicrob. Agents Chemother.
49: 2479-2486
[Abstract]
[Full Text]
-
Strahilevitz, J., Hooper, D. C.
(2005). Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin. Antimicrob. Agents Chemother.
49: 1949-1956
[Abstract]
[Full Text]
-
Seral, C., Barcia-Macay, M., Mingeot-Leclercq, M. P., Tulkens, P. M., Van Bambeke, F.
(2005). Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother
55: 511-517
[Abstract]
[Full Text]
-
Tran, J. H., Jacoby, G. A., Hooper, D. C.
(2005). Interaction of the Plasmid-Encoded Quinolone Resistance Protein Qnr with Escherichia coli DNA Gyrase. Antimicrob. Agents Chemother.
49: 118-125
[Abstract]
[Full Text]
-
Kugelberg, E., Lofmark, S., Wretlind, B., Andersson, D. I.
(2005). Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother
55: 22-30
[Abstract]
[Full Text]